LEADER 03075nam  2200649Ia 450 
001 9910456590803321
005 20200520144314.0
010   $a1-282-45484-6
010   $a9786612454844
010   $a0-309-13045-X
035   $a(CKB)2550000000010224
035   $a(EBL)3378570
035   $a(SSID)ssj0000410972
035   $a(PQKBManifestationID)11293010
035   $a(PQKBTitleCode)TC0000410972
035   $a(PQKBWorkID)10351764
035   $a(PQKB)10755782
035   $a(MiAaPQ)EBC3378570
035   $a(Au-PeEL)EBL3378570
035   $a(CaPaEBR)ebr10364020
035   $a(CaONFJC)MIL245484
035   $a(OCoLC)923280829
035   $a(EXLCZ)992550000000010224
100   $a20090930d2009      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aAddressing the threat of drug-resistant tuberculosis$b[electronic resource] $ea realistic assessment of the challenge : workshop summary /$fRobert Giffin and Sally Robinson, rapporteurs; Institute of Medicine of the National Academies
210   $aWashington, D.C. $cNational Academies Press$d2009
215   $a1 online resource (253 p.)
300   $a"The Institute of Medicine's (IOM's) Forum on Drug Discovery, Development, and Translation held a workshop in Washington, DC, on November 5, 2008"--p. 2.
311   $a0-309-13044-1 
320   $aIncludes bibliographical references.
327   $a""Reviewers""; ""Contents""; ""Tables, Figures, and Boxes""; ""Acronyms""; ""Summary""; ""1 Introduction""; ""2 The Global Spread of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis""; ""3 MDR TB Transmission, HIV Coinfection, and Transmission Control""; ""4 Diagnosis""; ""5 Infrastructure and Health Care Delivery Systems""; ""6 Global Systems for the Purchase and Delivery of TB Drugs""; ""7 Research on the Global Control of TB: Understanding the Role of Drugs, Vaccines, and Funding""; ""8 Strategies for Confronting the Global MDR and XDR TB Crisis""; ""References""
327   $a""Appendix A: Agenda""""Appendix B: Participant Biographies""; ""Appendix C: Partners In Health White Papera???Stemming the Tide of Multidrug-Resistant Tuberculosis: Major Barriers to Addressing the Growing Epidemic""
606   $aMultidrug-resistant tuberculosis$vCongresses
606   $aTuberculosis$vCongresses
606   $aDrug resistance$vCongresses
606   $aAntitubercular agents$vCongresses
608   $aElectronic books.
615  0$aMultidrug-resistant tuberculosis
615  0$aTuberculosis
615  0$aDrug resistance
615  0$aAntitubercular agents
676   $a616.9
701   $aGiffin$b Robert B$0906709
701   $aRobinson$b Sally$0620917
712 02$aInstitute of Medicine (U.S.).$bForum on Drug Discovery, Development, and Translation.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910456590803321
996   $aAddressing the threat of drug-resistant tuberculosis$92480017
997   $aUNINA

LEADER 01137nam a22002651i 4500
001 991002007719707536
005 20040116160749.0
008 040407s2000    it |||||||||||||||||eng  
035   $ab12856770-39ule_inst
035   $aARCHE-083639$9ExL
040   $aDip.to Scienze Storiche$bita$cA.t.i. Arché s.c.r.l. Pandora Sicilia s.r.l.
082 04$a338
100 1 $aBenfratello, Luigi$0485720
245 10$aResearch joint ventures and firm level performance /$cLuigi Benfratello and Alessandro Sembenelli
260   $aMilano :$bFondazione ENI Enrico Mattei,$c2000
300   $a21 p. ;$c21 cm
440  0$aNote di lavoro della Fondazione ENI Enrico Mattei ;$v13.2000
650  4$aImprese
700 1 $aSembenelli, Alessandro$eauthor$4http://id.loc.gov/vocabulary/relators/aut$0119413
907   $a.b12856770$b02-04-14$c16-04-04
912   $a991002007719707536
945   $aLE009 GEOG.COLL.14G/13$g1$i2009000312241$lle009$o-$pE0.00$q-$rl$s-  $t0$u0$v0$w0$x0$y.i13416595$z16-04-04
996   $aResearch joint ventures and firm level performance$91448447
997   $aUNISALENTO
998   $ale009$b16-04-04$cm$da  $e-$feng$git $h0$i1